Axelopran in Patients With Anti-PD-1 Refractory Metastatic or Locoregionally Unresectable Cutaneous Melanoma | MicrobiomeTrials← Back to trialsNCT07631325
Axelopran in Patients With Anti-PD-1 Refractory Metastatic or Locoregionally Unresectable Cutaneous Melanoma
RecruitingPHASE1, PHASE2INTERVENTIONAL
Trial Details
Start: 2026-07-31Est. Completion: 2028-07-31
Enrollment target: 28 participants Locations- UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, United States
Other microbiome trials you might be interested in
Recurrent Melanoma (Skin)Metastatic MelanomaMelanoma Stage IVMelanoma Stage III
In this first-in human, phase I/IIa study, the safety and efficacy of \[212Pb\]VMT01, an alpha-particle emitting therape…
Orange, United StatesEst. completion Dec 31, 2027
Melanoma, Cutaneous Malignant
This clinical trial is a prospective, multicenter, open-label, randomized, actively controlled, parallel-group Phase 3 c…
Phoenix, United StatesEst. completion Jan 2028
Unresectable/Metastatic Melanoma
The purpose of this study is to compare the effects on patients with metastatic melanoma of taking a government approved…
Victoria, AustraliaEst. completion Dec 31, 2027